)
Visual
earnings real time
Tyra Biosciences (TYRA) investor relations material
Tyra Biosciences Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary19 Nov, 2025
Pipeline and clinical progress
Lead drug dabogratinib, an FGFR3 selective inhibitor, is advancing in phase II studies for upper tract urothelial carcinoma, intermediate risk NMIBC, and achondroplasia.
FGFR3 is a key genetic driver in bladder cancers and skeletal dysplasias, with high positivity rates in early-stage disease.
Achondroplasia and other FGFR3-driven short stature conditions represent significant opportunities for targeted therapy.
Dabogratinib is the only oral FGFR3 selective drug in clinical development for these indications.
Phase II studies are enrolling, with initial data readouts expected in the first half of next year for NMIBC and in the second half for achondroplasia.
Efficacy and safety data
Erdafitinib, a pan-FGFR inhibitor, showed high efficacy but significant toxicity due to off-target effects; dabogratinib aims to match efficacy with improved safety.
Dabogratinib demonstrated a marked reduction in FGFR1/2-related toxicities, such as nail disorders and hyperphosphatemia, compared to erdafitinib.
At 40 and 60 mg doses, dabogratinib showed a clean safety profile, with minimal liver enzyme elevations.
The ongoing NMIBC study is testing 50 and 60 mg doses, targeting efficacy similar to erdafitinib but with better tolerability.
Initial 3-month complete response data from 20-30 patients is expected by mid-next year.
Market opportunity and physician adoption
FGFR3-driven bladder cancers represent a multi-billion dollar market due to high unmet need and patient volume.
Oral therapies are increasingly favored by urologists, who have adapted their practices to benefit economically from in-office dispensing.
The oral option is expected to drive a dynamic switch market, with physician and patient preferences shaping adoption.
Expansion into upper tract urothelial carcinoma addresses a high-burden, hard-to-treat population with few alternatives.
The oral FGFR3 inhibitor could offer a Gleevec-like opportunity for long-term disease management.
Oral NMIBC: How will it reshape urology practice?
How to optimize AHV without bone integrity issues?
UTUC: What defines the 'Gleevec-type' opportunity?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Tyra Biosciences earnings date
Q4 202527 Mar, 2026
Next Tyra Biosciences earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Tyra Biosciences Inc. is a clinical-stage biotechnology company specializing in the development of precision medicines targeted at Fibroblast Growth Factor Receptor biology. Leveraging its proprietary platform, Tyra Biosciences focuses on creating drugs through iterative molecular snapshots which aid in predicting genetic alterations and developing therapies for oncology and genetically defined conditions. The company is headquartered in Carlsbad, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage